Filter Results
:
(78)
Show Results For
- All HBS Web (78)
- Faculty Publications (36)
Show Results For
- All HBS Web (78)
- Faculty Publications (36)
←
Page 4 of
78
Results
- Career Coach
Jon Puz
Development & Sales), Deloitte Consulting (Consultant, Healthcare Strategy & Operations), Internships: Merrill Lynch Healthcare Investment Banking, Eli Lilly and Company
View Details
Eugene N. Beesley
depreciation and other expenses were cut. Though his tenure as CEO was brief, Beesley’s time at the helm of Eli Lilly allowed net sales to grow from $480 million in 1968 to just under $820 million in 1972.
View Details
Keywords:
Healthcare
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
Transformation at Eli Lilly & Co. (A) Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly...
View Details
Keywords:
Sean Silverthorne
- 01 Mar 2011
- News
Fixing What Ails the Drug Industry
at the 11th HBS Health Industry Alumni Association Conference. She joined Eli Lilly CEO John Lechleiter in addressing the November 4–6 event, titled “The Future of Therapy from the Leaders Who Create It.” So...
View Details
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
Bastianelli said. Also missing are the partnerships between academic and business communities that are common in the States, added Thomas G. Wellner, executive director of marketing at Eli Lilly and...
View Details
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate...
View Details
Keywords:
by Sean Silverthorne
- 24 Mar 2020
- Research & Ideas
These Coronavirus Heroes Show Us How Crisis Leadership Works
for COVID-19 and is currently able to run 1,000 tests per day. David A. Ricks, CEO of Eli Lilly. Under Ricks’ guidance, Lilly has teamed with AbCellera Biologics to find antibodies to disarm COVID-19....
View Details
- 29 Jun 2022
- Blog Post
Harvard Business School Announces the 2022-2023 Blavatnik Fellows
medicines. Hunter plans to use the Blavatnik Fellowship year to refine strategy and business development for the company’s novel drug delivery platform with his co-founders, Harvard Medical School Professor Dr. Wayne Lencer and Justin Wolfe, PhD. Hunter became...
View Details
- Web
Why Plume? To Make a Difference in the World - MBA
Eli Lilly Three Stories from HBS PRIDE for National Coming Out Day Admissions Events Check out our upcoming webinars, prospective student days, and information sessions on campus and around the world. –View...
View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707486 Corporate Venture Capital at Eli Lilly Harvard Business School Case 806-092 Reviews the role of corporate venture capital and its history...
View Details
Keywords:
Martha Lagace
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
influenced the industry by proving that intellectual property could be monetized through alliances with big pharmaceutical partners, according to Pisano. Genentech cut its first deal with Eli Lilly in 1982...
View Details
- 20 Apr 2016
- Research & Ideas
When CEOs Become Activists
which executive activism affected not only public opinion but also customer perceptions. Apple CEO Cook’s actions around the RFRA debate particularly intrigued the researchers. “You can see a business reason why the CEOs of Eli View Details
- 18 Dec 2012
- First Look
First Look: December 18
note:http://hbr.org/search/813096-PDF-ENG Cialis Lifecycle Management: Lilly's BPH Dilemma Ofek, Elie, and Natalie KindredHarvard Business School Case 513-005 How should Eli Lilly further develop and market...
View Details
Keywords:
Carmen Nobel
- 28 Apr 2009
- First Look
First Look: April 28, 2009
the company submits to the Food and Drug Administration. The case reviews Targanta's origins and "de-risking" of oritavancin, an antibiotic therapy for drug-resistant infections that was first invented at Eli View Details
Keywords:
Martha Lagace